Premium
Letter: choosing between ustekinumab and vedolizumab in anti‐TNF refractory Crohn's disease—the devil is in the detail. Authors' reply
Author(s) -
Alric Hadrien,
Amiot Aurélien,
Carbonnel Franck,
Meyer Antoine
Publication year - 2020
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.15888
Subject(s) - vedolizumab , ustekinumab , medicine , refractory (planetary science) , crohn's disease , crohn disease , dermatology , tumor necrosis factor alpha , disease , infliximab , immunology , physics , astrobiology